Description

Rapiglinide Vog 0.5 LD is a combination medicine containing Repaglinide and Voglibose, two antidiabetic agents used to help manage blood glucose levels in people with type 2 diabetes mellitus. These medicines work through different mechanisms to help control blood sugar, particularly around mealtimes. The exact composition and strength of each active ingredient should be verified on the product packaging. Repaglinide stimulates the pancreas to release insulin in response to meals, while Voglibose helps slow the digestion and absorption of carbohydrates in the intestine. When prescribed appropriately alongside dietary changes and physical activity, this combination may help improve post-meal blood glucose control. Rapiglinide Vog 0.5 LD should be used only under medical supervision. Uses Rapiglinide Vog 0.5 LD may be prescribed as part of a treatment plan for adults with type 2 diabetes when a healthcare professional considers combination therapy appropriate. Type 2 diabetes management: Helps control blood glucose levels in eligible patients. Post-meal blood sugar control: Repaglinide stimulates meal-related insulin release, while Voglibose helps reduce the rise in blood glucose after eating. Complementary diabetes management: May be used alongside a balanced diet, regular physical activity, and other treatment measures as directed by a doctor. This medicine is not intended for treating type 1 diabetes or diabetic ketoacidosis. Its suitability depends on individual medical needs and the approved product information. Benefits Rapiglinide Vog 0.5 LD combines two active ingredients that support blood sugar management through different mechanisms. Helps control post-meal glucose: Voglibose delays carbohydrate breakdown and absorption, helping reduce post-meal blood glucose spikes. Supports insulin release: Repaglinide stimulates pancreatic insulin secretion around mealtimes, helping the body manage rising blood sugar. Offers complementary action: The combination targets two processes involved in post-meal glucose regulation and may benefit appropriately selected patients. Supports an overall diabetes care plan: When combined with recommended lifestyle changes and regular monitoring, this medicine may help patients work toward their individual blood glucose targets. The effectiveness of treatment varies between individuals. The medicine does not replace a healthy diet, physical activity, or routine diabetes monitoring. Dosage The dosage of Rapiglinide Vog 0.5 LD must be determined by a doctor according to blood glucose levels, meal patterns, kidney and liver function, and other medicines being taken. Take the medicine exactly as prescribed and follow the product leaflet. Repaglinide is generally taken shortly before meals; combination-product timing should follow the specific prescription. Ask your doctor or pharmacist what to do if you skip a meal or miss a dose. Do not double a dose or change the prescribed schedule without medical advice. Monitor blood glucose as recommended by your healthcare professional. Side Effects Rapiglinide Vog 0.5 LD may cause side effects, including: Low blood sugar (hypoglycaemia) Dizziness, sweating, shaking, or weakness Abdominal discomfort or bloating Diarrhoea or increased intestinal gas Nausea or headache Hypoglycaemia can become serious. If you experience confusion, fainting, seizures, or difficulty remaining conscious, seek emergency medical assistance. Ask your healthcare professional how to recognise and manage low blood sugar. Precautions and Warnings Inform your doctor if you have kidney or liver disease, digestive disorders, or a history of recurrent hypoglycaemia. Tell your healthcare professional about all medicines and supplements you take, as some may affect blood glucose or interact with treatment. Avoid alcohol unless your doctor confirms it is safe, as it may increase the risk of blood glucose disturbances. Follow a consistent meal plan and do not ignore symptoms of low blood sugar. Pregnant or breastfeeding individuals should seek medical advice before using this medicine. Conclusion Rapiglinide Vog 0.5 LD, containing Repaglinide and Voglibose, may help manage type 2 diabetes by supporting meal-related insulin release and reducing post-meal glucose spikes. When prescribed appropriately, it can form part of a comprehensive diabetes management plan.